GlassScriptPhysician profile
Paul S Yim
NPI 1487644522
$3,920.63
in general payments reported to CMS, 2019-2025
30 companies · $477 in 2025
The $477 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $496 · 2021: $560 · 2022: $679 · 2023: $556 · 2024: $592 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,625.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $779.13 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $674.39 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $407.58 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.56 | 2019-2022 | |
| Novo Nordisk INC | $270.41 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $250.29 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $174.79 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $131.88 | 2021-2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $121.51 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $119.59 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $84.42 | 2020-2024 | Veozah |
| Allergan, INC. | $74.82 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $58.65 | 2019-2025 | Varivax, Enflonsia, M-M-R II |
| Abbott Laboratories | $56.99 | 2021-2023 | Proclaim |
| Glaxosmithkline, LLC. | $56.12 | 2020-2025 | Trelegy Ellipta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $47.21 | 2021-2022 | |
| Indivior INC. | $31.56 | 2019 | |
| Phadia US INC. | $29.20 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.58 | 2021 | |
| Corium, LLC | $27.75 | 2025 | Azstarys |
| Genentech USA, INC. | $26.77 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $24.94 | 2020 | |
| Orexo US, INC. | $23.73 | 2019 | |
| Sumitomo Pharma America, INC. | $18.20 | 2023 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $17.83 | 2023 | |
| Amgen INC. | $16.60 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.42 | 2025 | Caplyta |
| Seqirus USA INC | $16.01 | 2025 | Fluad, Flucelvax |
| Jazz Pharmaceuticals INC. | $13.93 | 2019 | |
| Snap Diagnostics LLC | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Yim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.